An editorial on phase 2 results from treating people with obesity or overweight but not diabetes with retatrutide, a triple hormone–receptor agonist, calls the weight loss achieved "unprecedented."
Treatment with retatrutide, an agonist to GLP-1, GIP, and glucagon receptors in one molecule, was associated with unprecedented drops in weight from people with or without type 2 diabetes in a pair of early studies.
Hypoglycemia rates didn t differ between weekly insulin icodec and daily glargine even when intentionally doubling and tripling the doses, although those parts of the study each lasted just 1 day.
New Soliqua 100/33 data shows improved blood sugar control without weight gain versus premixed insulin prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Lilly s SURPASS-1 results published in The Lancet show tirzepatide s superior A1C and body weight reductions versus placebo in adults with type 2 diabetes prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.